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This thesis describes the outcome -survival- of a large group of 186 consecutive patients
with chronic active hepatitis of various etiologies, and describes in detail the progress of
2l patients from this group with 'autroimmune' chronic active hepatitis maintained on
standardized immunosuppressive ttrerapy.
Idiopathic 'autoimmune'chronic active hepatitis (IAI-CAI[) is generally considered as a
primarily hepatocytic liver disease of unknown cause, charactaiued by (episodes of)
periportal and portal inflammation and piecemeal necrosis, with the potential to
progress to cinhosis or associated with cinhosis. It lasts 6 months or longer.
The introduction biefly reviews the current knowledge on IAI-CAH. This is put into a
historical perspective, definitions are summarized, clinical symptoms and differential
diagnoses arc mentioned, data on dismal prognosis in untreated disease and improved
prognosis in treated IAI-CAH are reviewed. Treatment options are summarized,
problems in the diagnosis and management of the disease are mentioned, and an
overview regarding pafilmeters of inflammation and liver function useful in monitoring
IAI-CAH is provided. Furthermore, the present knowledge on pathogenesis and
possible aetiologies of the disease is put in an immunological contexl Unreated IAI-
CAH has a high morbidity and mortality. Early mortality is typically due to liver failure,
while late mortality usually results from the complications related to cirrhosis.
Immunosuppressive therapy can reduce inflammation and enhance survival. Formation
of cinhosis can continue despite induction of 'remission' from CAH. Clinical,
histological and biochemical findings must all be considered in concert for decisions
concerning therapy. Data are scarce on early changes in inflammation and liver function
during immunosuppressive therapy. No optimal tests for the follow-up of IAI-CAH are
available. Histology forms the basis for the diagnosis of CAH, but may be insufficient
and impractical for follow-up once therapy has been started. Standard laboratory blood-
tests do not, accurately reflect morphology. Until now, limited information was available
regarding changes in hepatic functional capacity during immunosuppressive therapy of
IAI-CAH. This warranted a search into parameters of activity and hepatic functional
capacity in IAI-CAH.
Section I deals with patients and methods.
Chapter I provides data on the patients included in these studies.
Chapter 2 refers to the methods used in the studies.
In Chapter 3, we compared numerical histological scoring of activity with conventional
pathological descriptions of treated and untreated CAH. The proposed histological
activity score (HAS) correlated very well with conventional scores. In contrast to the
original method of scoring, we propose to leave fibrosiVcinhosis out of this score of
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activity. Maximum HAS is 18. HAS<I denotes the (virtual) absence of inflantmatory
infiltrate. A HAS of 2 or 3 usually denotes a histology similar to chronic persistent
hepatitis (CPID; 90Vo of biopsies with a histology similar to CPH when scored
conventionally, and 36Vo f biopsies with minimal CAH (CAHmin.), showed a HAS<3.
We therefore termed I<HAS<3 "partial histological remission" and propose to reserve
the term "complete histological remission" for HAS(I. We conclude that HAS
accurately reflected histological activity of CAH, and is more accurate than
conventional descriptions for serial measurement of molph<llogical activity of disease.
Furthermore, it enables comparison with other parameters.
In Chapter 4, three radioimmunoassays for the determination of the serum N-terminal
propeptide of collagen type III were compared in chronic active hepatitis: a new rapid
equilibrium type of assay based on the human propeptide, developed by Risteli and
Risteli, wzrs compared with the PIIINP RlA-gnost@ @ehring), and the 'PIIINP Fab
assay@'(Behring), both based on a reference bovine PIIINP antigen (col l-3) and
antibodies raised in rabbits. The correlation between the human PIIINP RIA and the
PIIINP RlA-gnost@ was excellent, with less correlation with the ?IIINP Fab assay@'.
The new human assay is therefore as accurate as the standard PIIINP RlA-gnost@ used
thus far, but it is not sensitive to smaller degradation producs. Therefore, unlike in the
PIIINP RlA-gnost@ @ehring), no serial dilutions of the sera and no 50Vo intercept
method for calculating the results ure necessary in this new PIIINP assay, since dre
standards and the serum samples give parallel inhibition curves. This solves the most.
important problems that have been inherenJ in the determination of PIIINP, and provides
a rapid reliable test. We used this tests in studies on PIIINP that will follow.
In Chapter 5, the establishment of a modified radioimmunoassay for the determination
of auoantibodies against 'liver-specific membrane lipoprotein (LSP)' is described. This
modification of the original procedure yielded a rapid, reproducible and quantitative
assay for determination of anti-LSP antibodies.
In section 2 Chapter 6, we performed an analysis of survival of all 186 consecutive
patients with CAH of various aetiologies included in the cunent study. 85(13) percent
of all 186 patients with CAH survived 5 years, 70(t4) percent survived 10 years,
557o(t5) survived 15 years, nd 40?o(!10) survived 20 years after diagnosis. Ages
between therapy groups and aetiological groups did not differ significantly. Cox's
proportional hazards estimation identified increasing age, presence of antiHBs, and no
therapy (patients receiving standard immunosuppression had the best prognosis) as
independant risk factors. Sex, presence or absence of antinuclear antibodies, anti-
smooth muscle antibodies, level of serum alanine aminotransferase or serum
cholinesterase did not influence survival. Most causes of deaths registered in patiens
with CAH were not directly related to the liver disease. Remarkably, there was a high
incidence of plasmocytoma.
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In Section 3, several parameters of inflammation and liver function, their relations, and
the changes during immunosuppressive therapy are evaluated in 2l patiens with
'autroimmune'CAH.
In Chapter 7, routine liver biochemistry in IAI-CAH before and during standardized
immunosuppression was serially analyzed. Serum alanine aminotransferase (ALT),
aspartate aminotransferase (AST) and gammaglobulin (GG) were elevated at the start
and improved considerably to normal median values with therapy. However, ALT and
AST remained elevated between one and three times the upper reference limit in about
half of the patients. Conjugated bilirubin was elevated, then normalized within two
months to normal values in all patients. Median unconjugated bilirubin was normal at
the start, nevertheless values declined within the first two months of therapy.
Chapter 8 describes histology and its changes during immunosuppressive th rapy (0, 2,
14 and 26 months). The high median HAS declined considerably within the first two
months of therapy, with further improvement during tlre next two years of tlrerapy. At
two months 67 percent of the patiens had already improved to, a HASS3. The fixed-
dose therapy schedule was able to improve histlrlogy in 957o of the patiens. A HAS<I
(bomplete histological remission') was achieved in 80 percent of the patients and
I<HAS<3 ('partial histological remission') in l0 percent of the patients within two years
of treatmenL Periportal and lobular inflammation had disappeared in all of these
patients in remission. Continuing decrease in portal and periportal inflammatory
activity, with disappearance of plasma cells and decrease in numbers of lymphocytes,
was observed during the two years of immunosuppressive therapy. Usually, after two
years only lymphocytes remained. IIFS was high (median score 3) and did not change
during therapy.
Chapter 9 shows tlr,at hepatic protein syntlresizing capacity, impaired in the majority of
ttte 21 AI-CAH patients, normalized in the course of two yean in all patients under
investigation, despite the presence of cirrhosis in all but one patient. This was reflected
in increasing and normalizing serum albumin (ALB), (pseudo-)cholinesterase (CFIE'),
plasma antithrombin III (AT III), and decreasing and normalizing activated partial
tlromboplastin time (APTI), usually already in the flrst 14 months of therapy. The
median prothrombin time frl) was slightly elevated but did not change during rherapy,
although there was a trend to a transient further increase into the abnormal range within
the first four weeks of therapy. CFIE, unlike ALB and AT III was still increasing within
the second year of therapy. Hence, CHE may be the most sensitive of the pararneters of
hepatic protein synthesizing capacity under investigation.
Chapter l0 shows that the acute-phase r sponse is depressed in CAH: serum values of
C-reactive prctein (CRP) are only slightly elevated during this inflammation of its
producing organ, and these levels still correlated to periporal inflammation scores. In
contrast o CRP, semm amyloid precursor A protein (SAA) levels are normal in CAH,
and slightly increase during therapy. SAA values are related to CFIE: its levels reflect
hepatic protein synthesizing capacity and not inflammation in CAH.
Chapter ll describes that the serum N-terminal propeptide of collagen type III (PIIINP)
is elevated in 'autoimmune' CAH. PIIINP values rapidly decrease in the lrst two
months of therapy. PIIINP levels finally normalize, or nearly normalize, but this can
ake 14 months of therapy despite a more rapid improvement in histology. This delay in
normalization, and the incomplet€ness of normalization in hatf of the patients, may
clarify why cirrhosis can develop during immunosuppressive therapy. PIIINP is
predominantly conelated to hisological inflammation and o ALT, but its levels also
show a weak inverse correlation !o CHE, probably reflecting reduced degtadation of
PIIINP in the liver during severely impaired liver function.
In Chapter 12, serum ALT and PIIINP were studied in 16 CAH relapses occurring
during therapy withdrawal in 9 patiens. During remission, ALT was below twice the
upper reference limit, and PIIINP was below the reference limit in all cases. Using two
or three times the upper reference limit of ALT as 'cut-off for diagnosis of CAH-
relapse, as recommended in the literature, ALT only rose above this limit median one
week before the peak-Al;L An increase of PIIINP above the reference limit occuned
weeks to months before the fak-ALI was reached. Using ALT, it was only possible to
detect relapse as early as with PIIINP if each patient served as his/her own control for
ALT, with the (arbinarily chosen) upper reference limit at 1.25 times the ALT value
obtained uring histological remission (HAS<3 and preferably HAS<1).
Section 4 describes ome immunological abnormalities in chronic active hepatitis, and
their clinical relevance. The results in Chapter 13 show that autoantibodies to 'liver-
specific membrane lipoprotein (LSP) were invariably present in patients with
'autoimmune' CAH requiring standardized immunosuppressive therapy. Tires declined
in all patiena during such therapy. In the course of two years anti-LSP became
undetectable in half of the patients, while it remained detectable in the other half. As
shown by others, presence of anti-LSP probably indicates ongoing stimulation of B-
lymphocytes as the result of a defect in inducers of LSP-specific T-suppressor
lymphocytes.
In Chapter 14, serum anti-LSP antibodies in 12 CAH relapses occurring during therapy
withdrawal in 9 patiens were studied. At the start of therapy withdrawal, all patients
were in histological remission, and in only one case anti-LSP was detectable. Weeks to
months before the peak-ALI was reached, anti-LSP became detectable where
previously undetectable (with one exception). A change from undetectable to detectable
anti-LSP preceded relapse, and it preceded its detection by the conventional serological
defhition of relapse (ALI>3x the upper reference limit). It also preceded "non-
remission" based on ALT exceeding two times the upper reference limit This supporu
the theory that in IAI-CAH anti-LSP should be undetectable betore considering to
withdraw immunosuppressive therapy.
Chapter 15 describes that autoantiMies to a soluble liver antigen (SLA) are present in
about l0 percent of our population of patients with idiopathic 'autoimmune' CAH. No
patients with anti liver-kidney-microsomal ntibodies type I (anti-LKMI) -denoting a
more severe type of IAI-CAH- were detected in this population. Therefore, our patients
with IAI could be divided into three of tre recently proposed four subtypes of IAI-CAH
with the help of ANA, SMA and SLA. Survival in these ttrree groups did not differ, and
presence or absence of the antibodies mentioned were not independant prognostic
factors. This questions the clinical signihcance of this classification of IAI-CAH in four
subtypes. However, the groups may have different aetiologies of IAI-CAH.
Chapter 16 shows that anti-cardiolipin antibodies (ACA), as detected by ELISA, were
not inftequent in CAH and 'CAH-related disorders' of various aetiologies, with the
highest prevalence and titres in IAI-CAH. In contrast, anti-DNA antibodies, detected by
immunofluorescence with the kinetoplast of Crithidia Luciliae as a substrate, were
absent in 98 percent of CAH patienls, allowing the possibility of an immunological
distinction from SLE. The prevalence of anti-DNA measured by ELISA was higher than
with the immunofluorescence mentioned, especially for anti-DNA antibodies of the IgM
class. This difference may be due to a difference in avidity of the anti-DNA antibodies
measured using both methods. From the results, it also followed that cross-reactivity
between ACA and anti-DNA was limited in CAH and, if present, probably only applies
to anti-DNA of low avidity.
Chapter l'l shows the high incidence and tiues of lgG-class anribodies to
cytomegalovirus-induced late antigens (CMV-LA) in IAI-CAH and HBsAg-positive
CAH. Frequently, anti-CMV-LA and anti-LSP were both present in IAI-CAH. However,
there was no significant correlation between presence of these antibodies. Binding of
anti-LSP in the radioimmunoassay for anti-LSP was not inhibited by addition of CMV-
LA. Antibodies to the defined CMV-induced antigens'immediate early antigen (IEA)'of
67 kD and to'membrane antigen (MA)'of 58 kD molecular weight were only positive in
patients with anti-CMV-LA IgG, not in patients with anti-LSP but without anti-CMV-
LA IgG. From these results, it can be deduced that an aetiological role of CMV in IAI-
CAH by molecular mimicry between CMV-induced membrane antigens and LSP is
highly unlikely. This does not exclude an aetiological role for CMV by means of other
pathways.
